Targeting breast cancer metastases using patient-derived models
Research Project 2 Proteogenomic-guided therapeutic targeting of breast cancer patient-derived xenograft metastases
This study is looking at breast cancer in patients of Black ancestry to create models that help us understand how aggressive types of breast cancer behave and spread, and to see if certain drug combinations, like selinexor, can effectively treat it, all with the goal of improving treatment for everyone.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Virginia Commonwealth University NIH-funded |
| Lab location | 1 site (Richmond, United States) |
| Project ID | NIH-10890853 on NIH RePORTER |
What this research studies
This research focuses on developing patient-derived xenograft (PDX) models from breast cancer patients, particularly those of Black ancestry, to better understand the genetic and proteomic profiles of aggressive breast cancer subtypes. The project aims to identify how these tumors spread to different organs and evaluate the effectiveness of specific drug combinations, including selinexor, in treating metastatic breast cancer. By utilizing these models, the research seeks to address disparities in breast cancer treatment and outcomes among different ancestral groups.
Who could benefit from this research
Good fit: Ideal candidates for this research are breast cancer patients, especially those of Black ancestry, who have been diagnosed with Basal-like Triple-Negative Breast Cancer.
Not a fit: Patients with non-metastatic breast cancer or those with other cancer types may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for patients with aggressive forms of breast cancer.
How similar studies have performed: Other research has shown promise in using patient-derived models to study cancer, indicating that this approach could yield valuable insights and therapeutic strategies.
Where this research is happening
Richmond, United States
- Virginia Commonwealth University — Richmond, United States (Active)
Researchers
- Principal investigator: Harrell, Joshua (Chuck) — Virginia Commonwealth University
- Study coordinator: Harrell, Joshua (Chuck)
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.